Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?”</title><author><name sortKey="Kane, Mark A" sort="Kane, Mark A" uniqKey="Kane M" first="Mark A." last="Kane">Mark A. Kane</name><affiliation><nlm:aff id="af0001">Mercer Island, WA,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Roudot Thoraval, Francois" sort="Roudot Thoraval, Francois" uniqKey="Roudot Thoraval F" first="Francois" last="Roudot-Thoraval">Francois Roudot-Thoraval</name><affiliation><nlm:aff id="af0002"><institution>Department of Public Health, AP-HP, Henri Mondor Hospital</institution>, Creteil,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Guerin, Nicole" sort="Guerin, Nicole" uniqKey="Guerin N" first="Nicole" last="Guerin">Nicole Guerin</name><affiliation><nlm:aff id="af0003">Antony,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Papaevangelou, Vassiliki" sort="Papaevangelou, Vassiliki" uniqKey="Papaevangelou V" first="Vassiliki" last="Papaevangelou">Vassiliki Papaevangelou</name><affiliation><nlm:aff id="af0004"><institution>Third Department of Pediatrics, University of Athens School of Medicine, 'Attikon' University Hospital</institution>, Athens,<country>Greece</country></nlm:aff></affiliation></author><author><name sortKey="Van Damme, Pierre" sort="Van Damme, Pierre" uniqKey="Van Damme P" first="Pierre" last="Van Damme">Pierre Van Damme</name><affiliation><nlm:aff id="af0005"><institution>Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute (VAXINFECTIO), Antwerp University</institution>, Antwerp,<country>Belgium</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27261211</idno><idno type="pmc">4994755</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994755</idno><idno type="RBID">PMC:4994755</idno><idno type="doi">10.1080/21645515.2016.1177689</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000E39</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E39</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?”</title><author><name sortKey="Kane, Mark A" sort="Kane, Mark A" uniqKey="Kane M" first="Mark A." last="Kane">Mark A. Kane</name><affiliation><nlm:aff id="af0001">Mercer Island, WA,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Roudot Thoraval, Francois" sort="Roudot Thoraval, Francois" uniqKey="Roudot Thoraval F" first="Francois" last="Roudot-Thoraval">Francois Roudot-Thoraval</name><affiliation><nlm:aff id="af0002"><institution>Department of Public Health, AP-HP, Henri Mondor Hospital</institution>, Creteil,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Guerin, Nicole" sort="Guerin, Nicole" uniqKey="Guerin N" first="Nicole" last="Guerin">Nicole Guerin</name><affiliation><nlm:aff id="af0003">Antony,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Papaevangelou, Vassiliki" sort="Papaevangelou, Vassiliki" uniqKey="Papaevangelou V" first="Vassiliki" last="Papaevangelou">Vassiliki Papaevangelou</name><affiliation><nlm:aff id="af0004"><institution>Third Department of Pediatrics, University of Athens School of Medicine, 'Attikon' University Hospital</institution>, Athens,<country>Greece</country></nlm:aff></affiliation></author><author><name sortKey="Van Damme, Pierre" sort="Van Damme, Pierre" uniqKey="Van Damme P" first="Pierre" last="Van Damme">Pierre Van Damme</name><affiliation><nlm:aff id="af0005"><institution>Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute (VAXINFECTIO), Antwerp University</institution>, Antwerp,<country>Belgium</country></nlm:aff></affiliation></author></analytic><series><title level="j">Human Vaccines & Immunotherapeutics</title><idno type="ISSN">2164-5515</idno><idno type="eISSN">2164-554X</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>ABSTRACT</title><p>Control of hepatitis B through routine infant immunization in more than 95% of countries has reduced the prevalence of chronic hepatitis carriers to less than 1%–2% in immunized cohorts of children even in high endemicity countries. In that context the authors of this editorial found the results of a paper by Gras et al in this issue concerning. They performed a Delphi survey of 37 French immunization experts and the results concluded that delayed hepatitis B immunization would cause “potential damage” only after 11 years. Large cohorts of French children and adolescents remain susceptible to hepatitis B infection. Given the high rates of immigration to France from areas of higher endemicity, the higher birth rate and degree of integration of these groups into the health system, plus the lower age of sexual debut and the use of injectable drugs in the general population, we cannot agree that a delay of 11 years is acceptable. Rates of adolescent immunization are quite low so relying on protection at this age will yield little in terms of population protection. Loss of confidence in Hepatitis B vaccine following disproved allegations that the vaccine caused Multiple Sclerosis persists in France, and we believe the results of this paper sends a damaging message to health workers and parents in France and beyond.</p></div></front></TEI><pmc article-type="editorial"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="publisher-id">KHVI</journal-id><journal-id journal-id-type="publisher-id">khvi20</journal-id><journal-title-group><journal-title>Human Vaccines & Immunotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">2164-5515</issn><issn pub-type="epub">2164-554X</issn><publisher><publisher-name>Taylor & Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27261211</article-id><article-id pub-id-type="pmc">4994755</article-id><article-id pub-id-type="publisher-id">1177689</article-id><article-id pub-id-type="doi">10.1080/21645515.2016.1177689</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?”</article-title><alt-title alt-title-type="running-authors">M. A. KANE ET AL.</alt-title><alt-title alt-title-type="running-title">HUMAN VACCINES & IMMUNOTHERAPEUTICS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kane</surname><given-names>Mark A.</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Roudot-Thoraval</surname><given-names>Francois</given-names></name><xref ref-type="aff" rid="af0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Guerin</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="af0003"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Papaevangelou</surname><given-names>Vassiliki</given-names></name><xref ref-type="aff" rid="af0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Van Damme</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="af0005"><sup>e</sup></xref></contrib><contrib contrib-type="author"><collab>on behalf of the Viral Hepatitis Prevention Board</collab></contrib><aff id="af0001"><label>a</label>Mercer Island, WA,<country>USA</country></aff><aff id="af0002"><label>b</label><institution>Department of Public Health, AP-HP, Henri Mondor Hospital</institution>, Creteil,<country>France</country></aff><aff id="af0003"><label>c</label>Antony,<country>France</country></aff><aff id="af0004"><label>d</label><institution>Third Department of Pediatrics, University of Athens School of Medicine, 'Attikon' University Hospital</institution>, Athens,<country>Greece</country></aff><aff id="af0005"><label>e</label><institution>Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute (VAXINFECTIO), Antwerp University</institution>, Antwerp,<country>Belgium</country></aff></contrib-group><author-notes><corresp id="an0001"><bold>CONTACT</bold> Mark A. Kane <email xlink:href="Mark.a.kane@gmail.com">Mark.a.kane@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>3</day><month>6</month><year>2016</year></pub-date><volume>12</volume><issue>8</issue><fpage seq="17">2053</fpage><lpage>2056</lpage><history><date date-type="received"><day>23</day><month>3</month><year>2016</year></date><date date-type="rev-recd"><day>29</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>8</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 Taylor & Francis</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Taylor & Francis</copyright-holder></permissions><self-uri content-type="pdf" xlink:href="khvi-12-08-1177689.pdf"></self-uri><abstract><title>ABSTRACT</title><p>Control of hepatitis B through routine infant immunization in more than 95% of countries has reduced the prevalence of chronic hepatitis carriers to less than 1%–2% in immunized cohorts of children even in high endemicity countries. In that context the authors of this editorial found the results of a paper by Gras et al in this issue concerning. They performed a Delphi survey of 37 French immunization experts and the results concluded that delayed hepatitis B immunization would cause “potential damage” only after 11 years. Large cohorts of French children and adolescents remain susceptible to hepatitis B infection. Given the high rates of immigration to France from areas of higher endemicity, the higher birth rate and degree of integration of these groups into the health system, plus the lower age of sexual debut and the use of injectable drugs in the general population, we cannot agree that a delay of 11 years is acceptable. Rates of adolescent immunization are quite low so relying on protection at this age will yield little in terms of population protection. Loss of confidence in Hepatitis B vaccine following disproved allegations that the vaccine caused Multiple Sclerosis persists in France, and we believe the results of this paper sends a damaging message to health workers and parents in France and beyond.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>hepatitis B</kwd><kwd>hepatitis B epidemiology</kwd><kwd>hepatitis B immunization</kwd><kwd>immunization delay</kwd><kwd>France</kwd></kwd-group><counts><fig-count count="0"></fig-count><table-count count="0"></table-count><ref-count count="22"></ref-count><page-count count="4"></page-count></counts></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E399 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000E399 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.32. |  |